Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | HCK | P08631 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.36 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26188303 | 0.93 | CCR1 (0.47) | CCR1CXCR3LIMK2KCNH2 | |
| SCHEMBL3223541 | 0.91 | CCR1 (0.57) | CCR1KCNH2 | |
| SCHEMBL3232495 | 0.91 | CCR1 (0.57) | CCR1KCNH2 | |
| SCHEMBL3224268 | 0.90 | CCR1 (0.42) | CCR1CXCR3TGFBR1LIMK2ABL1 | |
| SCHEMBL3225299 | 0.90 | CCR1 (0.42) | CCR1CXCR3TGFBR1LIMK2ABL1 | |
| SCHEMBL3232577 | 0.90 | CCR1 (0.50) | CCR1CXCR3TGFBR1PIK3CDABL1 | |
| SCHEMBL3234396 | 0.90 | CCR1 (0.50) | CCR1CXCR3TGFBR1PIK3CDABL1 | |
| SCHEMBL16519768 | 0.90 | CCR1 (0.44) | CCR1CXCR3TGFBR1PIK3CDABL1 | |
| SCHEMBL15096079 | 0.88 | CCR1 (0.58) | CCR1TGFBR1KCNH2 | |
| SCHEMBL15096077 | 0.87 | CCR1 (0.37) | CCR1CXCR3TGFBR1LIMK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2017-10-12 | — | — | US | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885CXCR3 9/4885TGFBR1 175/4885 |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885CXCR3 9/4885TGFBR1 175/4885 |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885TGFBR1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.